# Special Issue

# Advances in Gene Therapy

### Message from the Guest Editor

Genetic disorders present mild to fatal consequences to individuals, with limitations imposed beyond the patient to family members and with tremendously high societal costs. Gene therapy represents one of the most promising developments in modern medicine. The rise in new technologies in gene-based medicines is rapidly transforming the medical field from one of diagnosis and supportive care to one of numerous clinical trials and an increasing number of approved treatments. Gene therapy encompasses all work aimed at editing DNA or altering the transcript or epigenetic profile to incur a therapeutic benefit. These include studies relating to gene augmentation therapy, gene editing, or gene silencing. As of 2023, approximately 3900 gene therapy clinical trials have been completed. Each year, new therapies are brought onto the market with the potential to save the lives of numerous patients suffering from rare diseases. We solicit manuscripts relating to gene augmentation, gene editing, gene silencing, and epigenetic manipulation, where the intent is to develop therapy for rare diseases.

### Guest Editor

Dr. Ryan Butler
Departments of Psychiatry and Pediatrics, O'Donnell Brain Institute, UT Southwestern Medical Center, Dallas, TX 75390, USA

### Deadline for manuscript submissions

closed (10 May 2026)

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/si/223808

*Genes*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

# Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/journal/genes

MDPI

# About the Journal

## Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

## Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-2182, USA

## Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

**Journal Rank:**

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))